Literature DB >> 21975749

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.

Milo A Puhan1, Elena Gimeno-Santos, Madlaina Scharplatz, Thierry Troosters, E Haydn Walters, Johann Steurer.   

Abstract

BACKGROUND: Pulmonary rehabilitation has become a cornerstone in the management of patients with stable Chronic Obstructive Pulmonary Disease (COPD). Systematic reviews have shown large and important clinical effects of pulmonary rehabilitation in these patients. However, in unstable COPD patients who have recently suffered an exacerbation, the effects of pulmonary rehabilitation are less established.
OBJECTIVES: To assess the effects of pulmonary rehabilitation after COPD exacerbations on future hospital admissions (primary outcome) and other patient-important outcomes (mortality, health-related quality of life and exercise capacity). SEARCH STRATEGY: Trials were identified from searches of CENTRAL, MEDLINE, EMBASE, PEDRO and the Cochrane Airways Group Register of Trials. Searches were current as of March 2010. SELECTION CRITERIA: Randomized controlled trials comparing pulmonary rehabilitation of any duration after exacerbation of COPD with conventional care. Pulmonary rehabilitation programmes needed to include at least physical exercise. Control groups received conventional community care without rehabilitation. DATA COLLECTION AND ANALYSIS: We calculated pooled odds ratios and weighted mean differences (MD) using random-effects models. We requested missing data from the authors of the primary studies. MAIN
RESULTS: We identified nine trials involving 432 patients. Pulmonary rehabilitation significantly reduced hospital admissions (pooled odds ratio 0.22 [95% CI 0.08 to 0.58], number needed to treat (NNT) 4 [95% CI 3 to 8], over 25 weeks) and mortality (OR 0.28; 95% CI 0.10 to 0.84), NNT 6 [95% CI 5 to 30] over 107 weeks). Effects of pulmonary rehabilitation on health-related quality of life were well above the minimal important difference when measured by the Chronic Respiratory Questionnaire (MD for dyspnea, fatigue, emotional function and mastery domains between 0.81 (fatigue; 95% CI 0.16 to 1.45) and 0.97 (dyspnea; 95% CI 0.35 to 1.58)) and the St. Georges Respiratory Questionnaire total score (MD -9.88; 95% CI -14.40 to -5.37); impacts domain (MD -13.94; 95% CI -20.37 to -7.51) and for activity limitation domain (MD -9.94; 95% CI -15.98 to -3.89)). The symptoms domain of the St. Georges Respiratory Questionnaire showed no significant improvement. Pulmonary rehabilitation significantly improved exercise capacity and the improvement was above the minimally important difference (six-minute walk test (MD 77.70 meters; 95% CI 12.21 to 143.20) and shuttle walk test (MD 64.35; 95% CI 41.28 to 87.43)). No adverse events were reported in three studies. AUTHORS'
CONCLUSIONS: Evidence from nine small studies of moderate methodological quality, suggests that pulmonary rehabilitation is a highly effective and safe intervention to reduce hospital admissions and mortality and to improve health-related quality of life in COPD patients who have recently suffered an exacerbation of COPD.

Entities:  

Mesh:

Year:  2011        PMID: 21975749     DOI: 10.1002/14651858.CD005305.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  135 in total

Review 1.  Chronic obstructive pulmonary disease: consequences beyond the lung.

Authors:  Dinesh Shrikrishna; Nicholas S Hopkinson
Journal:  Clin Med (Lond)       Date:  2012-02       Impact factor: 2.659

Review 2.  Optimizing bronchodilation in the prevention of COPD exacerbations.

Authors:  Marc Miravitlles; Antonio Anzueto; José R Jardim
Journal:  Respir Res       Date:  2017-06-20

3.  International COPD Coalition Column: pulmonary rehabilitation-reaching out to our international community.

Authors:  Chris Garvey; Martijn A Spruit; Kylie Hill; Fabio Pitta; Takanobu Shioya
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

4.  [Outcome predictors for COPD patients hospitalized for acute exacerbation].

Authors:  M Spielmanns; F Axer; C Nell; A R Koczulla; T Boeselt; F Magnet; J H Storre; W Windisch
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-02       Impact factor: 0.840

Review 5.  Update on clinical trials in home mechanical ventilation.

Authors:  Luke E Hodgson; Patrick B Murphy
Journal:  J Thorac Dis       Date:  2016-02       Impact factor: 2.895

6.  What Does the Cochrane Collaboration Say about Respiratory Physiotherapy?

Authors: 
Journal:  Physiother Can       Date:  2012-04-05       Impact factor: 1.037

7.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

8.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

Review 9.  The pharmacological approach to the elderly COPD patient.

Authors:  Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

Review 10.  Chronic obstructive pulmonary disease (COPD) evidentiary framework.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.